Biolargo PFAS Treatment Technology Featured In The Disruptive Quarterly

Company leaders join environmental attorneys, academic researchers, and industry innovators in a special issue on forever chemicals and the protection of clean water

BioLargo, Inc., a cleantech and life sciences innovator, today announced the publication of the Q1/Q2 2026 edition of The Disruptive Quarterly (TDQ), titled "Water and Our Common Heritage: Facing the Challenge of Forever Chemicals." This latest TDQ edition brings together environmental attorneys, academic researchers, industry innovators, and artists around a single theme: protecting clean water in the face of PFAS contamination.

Guest editor and New York environmental attorney John Parker said the edition "highlights leading thought leaders and experts in addressing and mitigating the impacts of PFAS." Parker noted that the legal and technical challenges of forever chemicals are costly and lead to complex litigation, underscoring the value of thought leadership and sponsorship from companies such as BioLargo, Aquatech, and Roux.

BioLargo's inclusion in this special edition reflects the Company's growing role in national conversations surrounding PFAS remediation, environmental technology, and water policy. The publication includes an article by Tonya Chandler, President of BioLargo Equipment Solutions and Technologies, Inc., as well as a transcript of BioLargo President and CEO Dennis Calvert's keynote address from the Washington, D.C. Norwegian Embassy's seminar on "PFAS Forever Chemicals Challenges Facing Communities Across the Globe."

In addition to contributing to The Disruptive Quarterly, BioLargo executives have recently shared insights through the U.S. Department of Commerce's Environmental Technologies Trade Advisory Committee (ETTAC), the Forbes Business Council, and other national forums focused on innovation, sustainability, and environmental stewardship.

"Our technology and people are game changers in this space, so we are delighted to contribute to advancing public awareness and solutions," said Dennis Calvert, CEO of BioLargo, Inc. BioLargo's PFAS treatment platform includes its Aqueous Electrostatic Concentrator (AEC), a patented water treatment system designed to rapidly and affordably remove and concentrate per- and polyfluoroalkyl substances from contaminated water.

The AEC uses an electrostatic field and a proprietary membrane system to separate PFAS compounds from water in continuous flow, with BioLargo reporting greater than 99% PFAS removal, reduced PFAS-laden waste compared with conventional approaches, and energy costs as low as 30 cents per 1,000 gallons treated.

Other contributors to the latest TDQ include Atam P. Dhawan, PhD, Chief Strategic Innovation Officer and Senior Vice Provost for Research at the New Jersey Institute of Technology (NJIT), and Jeff Denholm, CEO and Founder of Strong Water Technologies and Home Dome Wildfire, which is working to replace the forever chemicals used in firefighting. "We are engineering the future of firefighting through innovation, environmental stewardship, and cutting-edge performance," Denholm said.

The PFAS edition combines scientific, policy, social, and artistic perspectives, including a gallery of artwork inspired by water protection and voices from the next generation, all in support of a single theme: the importance of protecting the clean water supply. It is available at thedisruptivequarterly.com.

About The Disruptive Quarterly
The Disruptive Quarterly, a publication of 22nd Century by Design Solutions, invites artists, writers, thought leaders, scientists, entrepreneurs, and creators to share work that can change minds, hearts, and industries. For more information, visit thedisruptivequarterly.com.

About BioLargo, Inc.
BioLargo, Inc. is a cleantech and life sciences innovator and engineering services solution provider. Our core products address PFAS contamination, achieve advanced water and wastewater treatment, control odor and VOCs, improve air quality, enable energy-efficiency and safe on-site energy storage, and control infections and infectious disease. Our approach is to invent or acquire novel technologies, develop them into product offerings, and extend their commercial reach through licensing and channel partnerships to maximize their impact. For more information, visit www.BioLargo.com.